trending Market Intelligence /marketintelligence/en/news-insights/trending/PfAZ6FWLyVbh1NEqVe0Paw2 content esgSubNav
In This List

Eli Lilly, Boehringer launch insulin in US

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Eli Lilly, Boehringer launch insulin in US

Eli Lilly & Co. and Boehringer Ingelheim Corp. launched Basaglar in the U.S. market.

The insulin will compete with Sanofi's Lantus to treat patients with type 1 diabetes and adults with type 2 diabetes.